Information Provided By:
Fly News Breaks for January 21, 2020
VERU
Jan 21, 2020 | 07:25 EDT
H.C. Wainwright analyst Yi Chen raised Veru's price target to $6 from $4.50 after VERU-944 reduced the frequency of hot flashes in a Phase 2 study. The data demonstrate that 50mg zuclomiphene could effectively reduce the frequency of ADT-induced hot flashes, which has no FDA-approved therapy, Chen tells investors in a research note. The analyst reiterates a Buy rating on the shares.
News For VERU From the Last 2 Days
There are no results for your query VERU
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.